Table 4.

Impact of 150 mg Elagolix QD for 12 Months or 200 mg Elagolix BID for 3 Months on the Mean 10‐Year Risk of Hip Fracture and Major Osteoporotic Fracture and NNH Analysis

Age strata, years	Mean 10‐year risk of fracture
	Not treated with elagolix	Treated with elagolix	Difference	NNH
150 mg QD for 12 months
50–59 (N = 830)
Hip fracture	0.45%	0.48%	0.03%	3979
Osteoporotic fracture	5.87%	5.93%	0.06%	1632
60–69 (N = 860)
Hip fracture	0.97%	1.01%	0.05%	2203
Osteoporotic fracture	8.40%	8.51%	0.11%	938
70–79 (N = 613)
Hip fracture	4.34%	4.49%	0.16%	643
Osteoporotic fracture	12.63%	12.85%	0.22%	454
200 mg BID for 3 months
50–59 (N = 830)
Hip fracture	0.45%	0.48%	0.02%	4252
Osteoporotic fracture	5.87%	5.93%	0.06%	1738
60–69 (N = 860)
Hip fracture	0.97%	1.01%	0.04%	2342
Osteoporotic fracture	8.40%	8.50%	0.10%	1000
70–79 (N = 613)
Hip fracture	4.34%	4.48%	0.15%	684
Osteoporotic fracture	12.63%	12.84%	0.21%	483

BID = Twice daily; NNH = number needed to harm; QD = once daily.